The FDA's Biologics Gatekeeper Just Walked Out (Again)

Ten days later, FDA Commissioner Marty Makary asked him to come back. And he did.

That whiplash moment captured everything strange about this era at the FDA: political pressure from unexpected corners, a commissioner playing cleanup, and a scientific leader caught in the crossfire. Now, less than a year after that rehiring, Prasad has walked away on his own terms, returning to academia as planned.

Makary, for his part, praised Prasad on the way out. He credited him with reducing the number of clinical trials required for some drug approvals, narrowing COVID-19 vaccine recommendations to people over 65 or those with risk factors, and launching new pathways for individualized medicines targeting ultra-rare genetic disorders.

Meet the New Boss (For Now)

Katherine Szarama steps into the acting director role after serving as Prasad's deputy since December 2025. The search for a permanent replacement is ongoing, and Makary has signaled he plans to name someone soon.

But "soon" is relative at an agency that's lost roughly half its senior leadership and about 3,500 employees since January 2025 under sweeping HHS cuts. The institutional knowledge walking out the door is staggering. Seasoned reviewers who understood the nuances of complex biologics applications have been replaced by vacancies or new faces still learning the ropes.

For biotech companies approaching key regulatory milestones (pre-submission meetings, advisory committee reviews, approval decisions), this brain drain creates real problems. One analyst described the churn as creating "real challenges" for operations, because the people who understood your drug's history at the agency may simply not be there anymore.

Why This Matters for Your Portfolio

CBER isn't some obscure regulatory backwater. It's the gatekeeper for some of the most exciting (and expensive) therapies in medicine: CAR-T cell treatments, gene editing platforms, next-generation vaccines, and xenotransplantation products. The center's 2026 agenda includes 19 new guidance documents covering everything from potency testing for gene therapies to expanding CAR-T treatments beyond cancer into autoimmune diseases.

Analysts expect 6 to 12 months of volatility during the leadership transition. Short-term approval delays are considered high risk, with some sponsors potentially facing 12- to 24-month setbacks if new requirements are imposed on previously agreed trial designs.

There's a silver lining, though. Richard Pazdur's presence at the Center for Drug Evaluation and Research (CDER, CBER's sibling center for traditional drugs) could improve coordination between the two centers. For hybrid products like certain gene therapies that straddle both jurisdictions, better collaboration might actually speed things up.

The novel therapy approval count dipped to 58 in 2025, a slight decline that coincided with the staffing upheaval. Whether that number recovers in 2026 depends heavily on who Makary picks as permanent director and how quickly that person can stabilize the ship.

The Bigger Picture

Zoom out, and the CBER saga is really a story about what happens when political turbulence hits a technical institution. Peter Marks, Prasad's predecessor, departed in early 2025 after HHS Secretary Robert F. Kennedy Jr. reportedly gave him the choice to resign or be fired. Marks, who had overseen the approval of the first CAR-T cell therapy and the first Ebola vaccine, left citing "misinformation and lies" eroding public trust in vaccines. He later joined Eli Lilly.

Since then, the center has cycled through leaders at a pace that would make a sports franchise blush. Each transition resets relationships with sponsors, reshuffles internal priorities, and introduces fresh uncertainty into timelines that were already measured in years.

For biotech investors and companies alike, the message is clear: watch the replacement announcement closely. The next CBER director will inherit a center under Congressional investigation, an industry demanding consistency, and a guidance agenda packed with consequential decisions. Whoever takes the job will need thick skin, deep scientific chops, and the political savvy to survive what has become one of the most turbulent seats in all of government.

No pressure.